Drug Trial Radar · NCT07891377
HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Feb 2028
Study completion May 2029
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II clinical trial to evaluate the efficacy and safety of different dosing regimens of HEC53856 tablets compared to rHuEPO injection in participants of the CIA trial.
Conditions
- Chemotherapy-induced Anemia
- Non-Myeloid Malignancy
Interventions
HEC53856 tabletDrug
The experimental cohort is divided into four groups: 20 mg once a day (QD) group, 40 mg QD group, 60 mg QD group, and 100 mg three times a week \[TIW\] group. Participants in the experimental cohort will take HEC53856 tablets orally either in the fasted state or after meals.
rHuEPO injectionDrug
rHuEPO Injection 36000 IU will be subcutaneously administered once weekly \[QW\].
Primary outcomes
What the sponsor says the trial is designed to measure.
- The compliance rate of hemoglobin (Hb) in trial participants at week 7Time frame: Week 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.